<DOC>
	<DOCNO>NCT02086227</DOCNO>
	<brief_summary>The primary objective study ascertain pharmacokinetics ( PK ) pharmacodynamics ( PD ) bioequivalence subcutaneous ( SC ) injection 1 mg ( 1 IU ) Glucagon ( Fresenius Kabi USA ) comparison reference product , GlucaGen速 ( Bedford Laboratories ) , 1 mg ( 1 IU ) , SC healthy adult subject .</brief_summary>
	<brief_title>Bioequivalence Fresenius Kabi USA , LLC Glucagon SC Injection Compared Glucagon Injection ( Bedford Laboratories )</brief_title>
	<detailed_description>This investigation serve basis Fresenius Kabi USA , obtain regulatory approval synthetic version Glucagon ( Fresenius Kabi USA ) , 1 mg ( 1 IU ) , SC . The aim conduct direct comparative pharmacokinetics pharmacodynamics 1 mg ( 1 IU ) synthetic Glucagon ( Fresenius Kabi USA ) GlucaGen速 ( manufacture Novo Nordisk A/S , market Bedford Laboratories ) , 1 mg ( 1 IU ) , SC healthy adult subject . This study examine comparison bioavailability pharmacokinetics 1 mg ( 1 IU ) Glucagon ( Fresenius Kabi USA ) subject receive period either single dose 1 mg ( 1 IU ) Glucagon ( Fresenius Kabi USA ) single dose GlucaGen速 ( Bedford Laboratories ) , 1 mg ( 1 IU ) , via subcutaneous injection . Blood sample collect three ( 3 ) time start 2 hour prior dose interval 4 hour post dose . The concentration glucagon glucose measure .</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Males female , 18 year old , body mass index ( BMI ) 18 30 kg/m2 inclusive . 2 . Good health determine lack clinically significant abnormality health assessment perform screen . 3 . Signed date informed consent form , meet criteria current guideline Medical Research Council ( MRC ) Canada FDA regulation . 4 . If female child bear potential prepared abstain sexual intercourse , use reliable nonhormonal method contraception study ( e.g . condom spermicide , IUD ) . Females use hormonal contraceptive must use method least 28 day prior throughout study . 1 . If female , pregnant , lactate likely become pregnant study . 2 . History allergy sensitivity glucagon history drug hypersensitivity intolerance , opinion Investigator , would compromise safety subject study . 3 . Significant history current evidence chronic infectious disease , system disorder organ dysfunction . 4 . Presence gastrointestinal disease history malabsorption within last year . Any history duodenal gastric ulcer . 5 . History psychiatric disorder occur within last two year require hospitalization medication . 6 . Presence medical condition require regular treatment prescription drug . 7 . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , omeprazole ; examples inhibitor : antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fluoroquinolones , antihistamine ) within 30 day prior administration study medication . 8 . Receipt drug part research study within 30 day prior dose . 9 . Drug alcohol addiction require treatment past 12 month . 10 . Donation significant loss whole blood ( 480 ml ) within 3 month plasma within 14 day prior dose . 11 . Positive test result HIV , Hepatitis B surface antigen Hepatitis C antibody . 12 . Unable , unwilling tolerate multiple venipuncture . 13 . Has difficulty fast consume standard meal provide . 14 . No prescription medication ( contraceptive ) use within 14 day prior initial study dose throughout time sample collection period . 15 . No overthecounter medication within 14 day prior dose throughout time sample collection period . 16 . No alcohol , caffeine/xanthine grapefruit contain food beverage ( e.g . chocolate , coffee , tea , cola , Fresca速 ) ingest within 3 day prior dose throughout time sample collection period . 17 . All subject saliva/urine test drug abuse check study period . Subjects positive result withdrawn study . 18 . All female subject screen pregnancy checkin study period urine pregnancy test . Subjects positive result withdrawn study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>